Health
Quick drug OK may affect safety
NEWS IN BRIEF — Posted April 14, 2008
Drugs approved by the Food and Drug Administration within two months of a deadline imposed by the Prescription Drug User Fee Act were more likely to be either withdrawn from the market or have black-box warnings added for safety reasons than were drugs approved at other times, according to a study in the March 27 New England Journal of Medicine.
Congress recently reauthorized PDUFA, which first became law in 1992. It allows the FDA to collect user fees from pharmaceutical companies in exchange for faster decisions on applications for marketing approval. Under the measure, 90% of approval decisions are to occur within 10 months of submission.
The law has generated controversy from some who object to drug firms paying the salaries of those who approve their products. The study authors concluded that their findings "suggest potential adverse effects of the deadlines governing FDA drug review. There are many ways to accelerate regulatory processes, most notably by providing more staff, which can be accomplished as readily by appropriations as by user fees," they wrote.
Note: This item originally appeared at http://www.ama-assn.org/amednews/2008/04/14/hlbf0414.htm.












